The drug is designed to treat T-cell acute lymphoblastic leukemia (T-ALL) and T-cell lymphoblastic lymphoma (T-LBL) patients whose disease has not responded to, or has relapsed following, treatment with at least two chemotherapy regimens.
Atriance will now be considered for final marketing approval by the European Commission, which normally takes place within 90 days.